JP2017516784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516784A5 JP2017516784A5 JP2016569606A JP2016569606A JP2017516784A5 JP 2017516784 A5 JP2017516784 A5 JP 2017516784A5 JP 2016569606 A JP2016569606 A JP 2016569606A JP 2016569606 A JP2016569606 A JP 2016569606A JP 2017516784 A5 JP2017516784 A5 JP 2017516784A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- pharmaceutically acceptable
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462003798P | 2014-05-28 | 2014-05-28 | |
| US62/003,798 | 2014-05-28 | ||
| US201462088200P | 2014-12-05 | 2014-12-05 | |
| US62/088,200 | 2014-12-05 | ||
| PCT/US2015/032990 WO2015184145A1 (en) | 2014-05-28 | 2015-05-28 | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516784A JP2017516784A (ja) | 2017-06-22 |
| JP2017516784A5 true JP2017516784A5 (cg-RX-API-DMAC7.html) | 2018-07-05 |
| JP6648040B2 JP6648040B2 (ja) | 2020-02-14 |
Family
ID=54699806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569606A Active JP6648040B2 (ja) | 2014-05-28 | 2015-05-28 | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10238630B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3148336B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6648040B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015184145A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5226304B2 (ja) | 2004-06-03 | 2013-07-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハリコンドリンｂ類似体の調製用中間体 |
| PT2415470T (pt) | 2009-03-30 | 2016-08-31 | Eisai R&D Man Co Ltd | Composição de lipossomas |
| WO2014208774A1 (en) | 2013-06-26 | 2014-12-31 | Eisai R&D Management Co., Ltd. | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
| ITUB20159206A1 (it) * | 2015-12-22 | 2017-06-22 | Olon Spa | Forme cristalline e amorfe di olaparib |
| EP3449921B1 (en) * | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| EP3463337A4 (en) | 2016-06-06 | 2020-02-12 | Beyondspring Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| SG11201907023UA (en) | 2017-02-01 | 2019-08-27 | Beyondspring Pharmaceuticals Inc | Method of reducing neutropenia |
| KR20190111116A (ko) * | 2017-02-06 | 2019-10-01 | 시티 오브 호프 | 암의 치료 |
| MX2019011496A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| KR20200018436A (ko) | 2017-05-09 | 2020-02-19 | 테사로, 인코포레이티드 | 암 치료를 위한 조합 요법 |
| CA3063715A1 (en) * | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
| CN107098862A (zh) * | 2017-06-05 | 2017-08-29 | 山东裕欣药业有限公司 | 一种奥拉帕尼二水合物及其制备方法 |
| EA202090573A1 (ru) * | 2017-09-26 | 2020-09-07 | Тесаро, Инк. | Составы нирапариба |
| JP2020536066A (ja) | 2017-09-30 | 2020-12-10 | テサロ， インコーポレイテッド | 癌を治療するための併用療法 |
| CN111182923A (zh) | 2017-10-06 | 2020-05-19 | 特沙诺有限公司 | 组合疗法及其用途 |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| MX2020008258A (es) * | 2018-02-05 | 2020-11-13 | Tesaro Inc | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. |
| JP2021522848A (ja) * | 2018-05-15 | 2021-09-02 | オンコロジー ベンチャー アーペーエス | 癌患者における薬物応答性を予測する方法 |
| US20220072167A1 (en) * | 2019-01-04 | 2022-03-10 | Actinium Pharmaceuticals, Inc. | Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody Radioconjugates |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| US20240197730A1 (en) * | 2021-04-09 | 2024-06-20 | Cardiff Oncology, Inc. | Cancer treatment using parp inhibitors and plk1 inhibitors |
| JP2024513505A (ja) | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
| WO2024054898A1 (en) * | 2022-09-08 | 2024-03-14 | Cardiff Oncology, Inc. | Onvansertib and parp inhibitor combination |
| WO2024055039A1 (en) | 2022-09-11 | 2024-03-14 | Cardiff Oncology, Inc. | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer |
| WO2024137738A1 (en) * | 2022-12-22 | 2024-06-27 | The Board Of Regents Of The University Of Oklahoma | Combinations of poly (adp-ribose) polymerase (parp) inhibitors and heteroarotinoids and methods of use as cancer treatments |
| WO2024191805A1 (en) * | 2023-03-10 | 2024-09-19 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653341B1 (en) * | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| PL2209375T3 (pl) * | 2007-10-03 | 2014-12-31 | Eisai Inc | Związki, kompozycje i metody stosowania inhibitorów PARP |
| EP2686441B1 (en) | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| CN103997894B (zh) | 2011-07-29 | 2016-08-24 | 麦迪韦逊前列腺治疗股份有限公司 | 乳癌的治疗 |
-
2015
- 2015-05-28 WO PCT/US2015/032990 patent/WO2015184145A1/en not_active Ceased
- 2015-05-28 US US15/314,200 patent/US10238630B2/en active Active
- 2015-05-28 EP EP15799685.1A patent/EP3148336B1/en active Active
- 2015-05-28 JP JP2016569606A patent/JP6648040B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516784A5 (cg-RX-API-DMAC7.html) | ||
| EP3148336B1 (en) | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| TWI361689B (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
| Rajawat et al. | Therapeutic targeting of poly (ADP‐ribose) polymerase‐1 (PARP1) in cancer: Current developments, therapeutic strategies, and future opportunities | |
| JP5551589B2 (ja) | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 | |
| TW200932239A (en) | PARP inhibitor compounds, compositions and methods of use | |
| JP2020516693A5 (cg-RX-API-DMAC7.html) | ||
| EP3969050A1 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| AU2017205749B2 (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| CN105120663A (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| KR20180129917A (ko) | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 | |
| Ali et al. | Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers | |
| JP2013511526A5 (cg-RX-API-DMAC7.html) | ||
| CN101484443A (zh) | 放射线治疗增强剂 | |
| Goldman et al. | MA07. 05 phase 1b/2 study of combined HER inhibition in refractory EGFR-mutated metastatic non-small cell lung cancer (NSCLC) | |
| Fecher et al. | Effectively targeting BRAF in melanoma: a formidable challenge. | |
| Cao et al. | Poly (ADP-Ribosyl) polymerase 1 inhibitors: A patent review | |
| CN111777621B (zh) | 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途 | |
| Gibson et al. | Updates on drug discovery in ovarian cancer | |
| CN118019537A (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| TW202508573A (zh) | 用於治療癌症之組合療法 | |
| WO2025212165A1 (en) | Targeted heterobifunctional small molecule proteolysis targeting chimeras | |
| WO2025250569A1 (en) | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors | |
| WO2025245463A1 (en) | Combination therapies | |
| WO2025245463A9 (en) | Combination therapies |